Obesity · Medical DeviceSafety Signalregulatorynear-term

Allurion Gastric Balloon Safety Update: Risks of Obstruction and Perforation

Importance8/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/13/2026, 12:35:03 AM

Assessment confidence: 56% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The updated safety information regarding the Allurion Gastric Balloon highlights significant risks that could affect patient safety and market perception. This situation necessitates close monitoring of regulatory responses and potential shifts in competitive dynamics within the obesity treatment sector. Regulatory context from MHRA (MHRA safety review gives UK plasma donations go ahead) supports the near-term read. Assessment grounded in 18 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio and strategy teams should assess the risk management strategies and communication plans regarding the safety of the Allurion Gastric Balloon. The strongest clinical anchor is Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight (ClinicalTrials.gov), sponsor/company relevance (lilly). In Obesity · Medical Device, 2 regulatory and 4 competitive items passed relevance filtering for medical device regulatory agencies.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Approves Supplemental Application for Wegovy (Semaglutide).

Regulatory Outlook

Regulatory risk is concentrated around MHRA safety review gives UK plasma donations go ahead (MHRA). Moderate corpus alignment. Relevant agencies in corpus: MHRA, FDA. The risks associated with the Allurion Gastric Balloon could prompt regulatory scrutiny, affecting approval processes and necessitating updates to safety communications and labeling.

Key Risks

Elevated high regulatory exposure for medical device regulatory agencies could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.

Key Opportunities

The safety concerns may lead to decreased sales and market share for the Allurion Gastric Balloon, as healthcare providers and patients may seek alternative obesity treatment options.
Upside for medical device regulatory agencies may improve if Safety and Efficacy of the Irreversible Electroporation (IRE) System for Adenotonsillar Hypertrophy in Children (ClinicalTrials.gov) delivers favorable follow-through.
Based on viral evolution, increases in seasonal infections, and facilitation of delivery, an annual combination vaccine simultaneously targeting influenza and SARS-CoV-2 would benefit public health.
Upside for medical device regulatory agencies may improve if Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain. (PubMed) delivers favorable follow-through.
Portfolio and strategy teams should assess the risk management strategies and communication plans regarding the safety of the Allurion Gastric Balloon.

What Would Change This Assessment

This becomes more urgent if Monitor for any regulatory actions, updates on safety communications, and changes in market share among obesity treatment devices.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

MHRA safety review gives UK plasma donations go ahead
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
Office of New Drugs Custom Medical Queries (OCMQs) for Safety Signal Detection in Clinical Trial Data - 06/23/2026
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Safety and Efficacy of the Irreversible Electroporation (IRE) System for Adenotonsillar Hypertrophy in Children
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Physical Restraints in Intensive Care Unit Patients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and Efficacy of Selective Intra-Arterial Cooling Infusion Combined With EVT in Acute Ischemic Stroke
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Clinical Trial to Investigate the Efficacy and Safety of Plant-derived Cetylated Fatty Acids (CFA) on Knee Pain and Stiffness in Healthy Adults With Persistent Knee Pain
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Approves Supplemental Application for Wegovy (Semaglutide)
Humanexa Signalshigh relevance
Entity match (obesity treatment market)
FDA Alerts on Non-Sterile BD ChloraPrep Applicators in Medline Convenience Kits
Humanexa Signalsmedium relevance
Moderate corpus alignment
Elranatamab shows robust efficacy and favorable safety in relapsed/refractory multiple myeloma
Humanexa Signalsmedium relevance
Moderate corpus alignment

A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and safety of ultrasound ablation for uterine fibroids in patients with abdominal surgical scars on the acoustic pathway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Osmotic dilators vs. Foley balloons: Bayesian secondary analyses of the DILAFOL trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and immunogenicity of COVID-19-Influenza Combination nanoparticle vaccine (CIC) containing SARS-CoV-2 recombinant spike and quadrivalent influenza hemagglutinin with Matrix-M® adjuvant: A phase
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

medical device regulatory agencies
Allurion
obesity treatment market

Commercial impact

medium

The safety concerns may lead to decreased sales and market share for the Allurion Gastric Balloon, as healthcare providers and patients may seek alternative obesity treatment options.

Regulatory impact

high

The risks associated with the Allurion Gastric Balloon could prompt regulatory scrutiny, affecting approval processes and necessitating updates to safety communications and labeling.

What to watch

Monitor for any regulatory actions, updates on safety communications, and changes in market share among obesity treatment devices.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.